177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Lutetium Lu 177 Vipivotide Tetraxetan
Related studies linked through entity extraction aliases.
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Status
- RECRUITING
- Phase
- PHASE2
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
- Status
- RECRUITING
- Phase
- PHASE2
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
- Status
- RECRUITING
- Phase
- PHASE2
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
- Status
- RECRUITING
- Phase
- PHASE2
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2